Fairfax Financial Holdings Limited

Fairfax said operating income from insurance and reinsurance, adjusted to an undiscounted basis and before risk margin, was $1.1 billion in Q2 2026. Underwriting income was $459 million versus $427 million a year ago, and the combined ratio was 93.1% versus 93.3% in Q2 2025. Interest and dividend income was $737 million, up 11% year over year from $660 million. Profits of associates were $43 million versus $131 million last year, and net gains on investments were $769 million. Net earnings were $1.4 billion in the quarter and $2.1 billion for the first six months; book value per share was $1,304.39, up 4.8% from year-end 2025 adjusted for the $15 dividend. Gross premium written was $9.4 billion, up 4.1% year over year. For the balance sheet, the holding company had $2.3 billion of cash and investments, the $2 billion revolver was undrawn, and the pretax excess of fair value over carrying value of noninsurance associates and market-traded consolidated subsidiaries was $4.4 billion. Management did not provide formal earnings guidance, but said it still thinks about $1 billion of income from associates and consolidated investments is a reasonable combined reference point, and it expects interest and dividend income to be supported by portfolio growth and higher reinvestment rates.

Peter Clarke framed the quarter as another strong one and stressed that Fairfax’s model still benefits from underwriting discipline, diversification, and long-term capital allocation. He said pricing is softening, especially in North American property, and the response is to prioritize the bottom line and shift toward higher-margin business rather than chase growth. He also emphasized the appeal of international operations, which he said are growing faster and now make up a meaningful and rising share of the business.

Amy Sherk highlighted the main transactions and balance-sheet items. She detailed the $1.9 billion Poseidon sale, which generated an $838 million realized gain, explained the Kennedy-Wilson structure through Kona BidCo, and reviewed upcoming deals including Andrew Peller at approximately $233 million, Sleep Country’s acquisition of Sleep Number for approximately $530 million, Fairfax India’s planned increase in IIFL Capital to a minimum of 51% for approximately $417 million, and the Eurobank/Eurolife and ERBA transactions. She also noted holding company liquidity of $2.3 billion, an undrawn $2 billion revolver, total debt to total capital of 28% versus 26.2% at year-end 2025, and common shareholders’ equity of $26 billion after buybacks, dividends, and foreign-currency-related OCI losses.

Analysts focused on softening in property and possibly casualty pricing, and management said the pressure remains greatest in property, with some signs it could spread into casualty. Peter Clarke said Fairfax is responding by tightening portfolio selection and leaning into international business, which he said is less pressured. Questions on the Fairfax stock TRS and buybacks were met with the answer that the company still sees its shares as undervalued, even though it trimmed about 24% of the TRS position. Management also addressed leverage and float, saying float is a long-term compounding priority and that recent debt issuance mainly replaced preferred shares on better terms, while interest and dividend income is viewed as a sustainable step-up rather than a one-time boost.